A representation of the EGFR protein, which plays a role in the progression of lung tumors driven by mutations in the KRAS protein. ©bbiolution GmbH

A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung tumours.

Novimmune's CD47xCD19 bi-specific antibody. © Novimmune SA

Swiss Novimmune SA has exclusively sold a licence option on its lead product NI-1701 (now renamed TG-1801), a bispecific anti-CD47/anti-CD19 antibody designed to trea B-cell blood cancers, to TG Therapeutics Inc.

© Mack Brooks Exhibitions

For two days, innovation in synthetic and bio-based fine chemicals will be in the focus of experts who meet at Chemspec Europe in Cologne (20-21 June, 2018, Koelnmesse).

FMI headquarters in Cambridge, MA. © Lynwell Associates

Three years ago Roche acquired a majority in shares of Foundation Medicines Inc (FMI), a specialist in cancer panel sequencing, which has build a huge database with cancer mutation profiles. Now Roche paid US2.4bn to complete the take-over.

Methicillin-resistant Staphylococcus aureus have become a problem in hospitals. © CDC

Researchers at French antibiotics specialist Deinobiotics SAS, a subsidiary of Deinove SA, and German researchers announces the discovery of a new class of resistance breaking antibiotics that kill MRSA or S. pneumoniae effectively.

Following a letter of about 1,000 EPO patent examiners , also patent attorneys have send an open letter to the European Patent Office (EPO), criticising its outgoing president for having established work routines that are set to lower quality of European patents.

Structure of Adrecizumab. © Adenomed AG

Adrenomed AG announced the publication of three scientific papers revealing how its adrenomedullin-targeting Phase II sepsis antibody Adrecizumab reverses vascular hyperpermeability in sepsis.

Antibiogramm. © Uwe Gille/wikipedia

As first regulatory body in the world, the FDA has presented a market-driven reimbursement mechanism for antibiotics that may incentivise drug development in a niche market with currently low return on investment. 

Øystein Soug, CEO of Targovax. © Targovax ASA

Despite a 6-month improvement of 2-year-overall survival in pancreatic cancer patients, Norwegian cancer immunotherapy specialist Targovax ASA will terminate development of TG01 in this indication. Instead, development of RAS neoantigen-targeting cancer vaccines will be pushed in colorectal cancer.

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec's CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus' programmed T cell therapies. © Miltenyi Biotec

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price.